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Abstract: Background: Evaluation of therapies for Parkinson’s disease (PD) may benefit from objective
quantification of the separate movement components of bradykinesia (i.e., velocity, amplitude, and rhythm).
This study evaluated the sensitivity and reliability of parameters derived from recently available optical hand
tracking techniques for patient-friendly, automated quantification of bradykinesia of the upper extremity in PD.
Methods: Fifty-seven patients with PD and 57 healthy individuals (controls) performed repetitive finger
tapping (RFT), alternating hand movements (AHM), and alternating forearm movements (AFM). Movement
components of bradykinesia (i.e., velocity, frequency, amplitude, hesitations, and halts) were quantified using
optical hand tracking. Reliability was quantified using intraclass correlation coefficients in a subgroup of 12
patients with PD and 12 controls (test-retest) and in all 57 controls (intra-trial).
Results: RFT and AHM were successfully recorded in 94% of all participants. Movement components differed
between patients with PD and controls and were correlated with clinical ratings. Velocity and halt duration
appeared to be most useful (i.e., the largest difference between the PD and control groups, good reliability)
for the quantification of RFT, whereas frequency appeared to be most useful for the quantification of AHM.
Other variables, such as frequency and amplitude of RFT, showed poor test-retest reliability, because they
were susceptible to changes in movement strategy. AFM was excluded from the analysis because of
problems with hand recognition.
Conclusion: Novel optical hand tracking techniques yield promising results for patient-friendly quantification
of bradykinesia of the upper extremity in PD. Future work should aim to optimize optical hand tracking and
reduce susceptibility to changes in strategy.
Bradykinesia is the cardinal motor manifestation and is required
to diagnose Parkinson’s disease (PD).1 It is characterized by slow-
ness of movement, associated with a decrement in amplitude or
speed, and with hesitations or halts as movements are continued.1
Motor impairments in PD are commonly assessed with the
Unified PD rating scale (International Parkinson and Movement
Disorders Society [MDS]-UPDRS),2 which addresses bradyki-
nesia of the upper limbs by means of 3 items (Items 3.4–3.6) on
repetitive finger and hand movements. For each item, a
combination of movement parameters (i.e., [progressive reduc-
tion of ] speed and amplitude, and the occurrence of interrup-
tions of rhythm) is simultaneously rated on a 5-point scale.
Recent work shows that the translation of what meets the
eye into 5-point rating categories is rather ambiguous. A com-
parison of the separate evaluation of 3 component scores of
movement (speed, amplitude, and rhythm) with the MDS-
UPDRS ratings of bradykinesia revealed that the majority of
clinicians based their clinical ratings mainly on amplitude,
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whereas others based their judgment on speed or rhythm.3 Such
different rating strategies may influence inter-rater reliability and
the evaluation of treatment effects, because different compo-
nents of movement may show a differential response to treat-
ment (e.g., speed is the component most responsive to
dopaminergic medication).4 Based on these findings, Heldman
et al.3 argued that quantifying the subcomponents of motion
separately may enable more accurate evaluation of interventions
in clinical care and research.
Although clinical scales and patient-reported outcomes are
still the primary assessment tools or endpoints in PD clinical
care and research, there is a growing awareness that “technol-
ogy-obtained measures” may contribute to patient management
by improving the sensitivity, accuracy, reproducibility, and fea-
sibility of objectively capturing the full complexity and diversity
of changes in motor behavior.5 New technologies for the
objective quantification of bradykinesia in PD thus should aim
for higher resolution and improved sensitivity to capture the
nuances of movement. A recent study demonstrated that, com-
pared with clinical ratings (MDS-UPDRS and the Modified
Bradykinesia Rating Scale6), inertial measurement units (IMUs)
attached to the thumb and index finger were more sensitive to
subtle changes in motor performance associated with changes of
stimulation parameters of the subthalamic nucleus.7
A broad range of currently available techniques can objec-
tively quantify bradykinesia in the laboratory or in ambulatory
settings.5,8–10 However, most of these techniques require the
attachment of sensors or markers to the fingers and/or hand,
which can affect the movement, requires preparation time, and
may depend on the correct execution of a calibration proce-
dure. Other techniques based on a keyboard11–13 or tablet14, are
easy to use but only provide information about the contact
phase rather than the full movement cycle.
In this study, we evaluated the potential of optical hand track-
ing (OHT) for separately quantifying the movement components
of bradykinesia in PD, which may improve progression monitor-
ing and enable more accurate evaluation of (novel) therapies.
Patients and Methods
Participants
For this cross-sectional study, we recruited 57 patients with PD
who fulfilled the UK PD Brain Bank criteria15 from the outpa-
tient clinic of the Department of Neurology at Leiden Univer-
sity Medical Center (for patient characteristics, see Table 1).
Patients were excluded if they had disorders of the central ner-
vous system other than PD or other conditions that could affect
motor function of the upper extremity. All patients were
allowed to take their routine PD medications. Fifty-seven
healthy controls (23 women; mean  standard deviation age,
63.8  7.6 years) who were sex-matched and age-matched
(3 years) to the patients, were recruited through advertise-
ments and from a database of volunteers who had participated
in previous studies. Healthy controls had no history of disorders
affecting the function of the upper extremities.
Test-retest reliability was evaluated in a subgroup of 24 par-
ticipants (12 patients with PD and 12 controls) who repeated
the test after 1 week at the same hour of the day. Informed
consent was obtained according to the Declaration of Helsinki.
The Ethical Committee of the Leiden University Medical Cen-




In all 57 patients, repetitive finger tapping with the thumb and
index finger (RFT) (Item 3.4 of the MDS-UPDRS), alternating
hand movements (AHM) (opening and closing of the hand;
Item 3.5), and alternating forearm movements (AFM) (prona-
tion and supination; Item 3.6) were each scored according to
the MDS-UPDRS guidelines by a certified researcher. Scores
were rated on a scale ranging from 0 (normal; no problems) to
4 (severe; cannot or can only barely perform the task because of
slowing, interruptions, or decrements). Participants who
repeated the test after 1 week rated the perceived change in
function of the arm/hand on an 11-point numeric rating scale
(0, much worse; 5, unchanged; 10, much better).
Optical hand tracking
The 3 tasks (RFT, AHM, and AFM) were evaluated in all par-
ticipants using OHT (see Fig. 1A). The system comprised a sen-
sor (ASUS Xtion Pro 2.0; ASUSTeK Computer Inc., Taipei,
Taiwan), consisting of an infrared laser transmitter and an infra-
red camera providing depth data, in combination with a 3Gear
software development kit (SDK v 0.9.32; 3Gear Systems Inc.,
San Francisco, CA). The sensor was mounted on an adjustable
pole hanging from the ceiling, about 0.70 m above the hands of
the participants when arms were outstretched in front of the
shoulders. Computer graphics algorithms within the SDK,
which were trained to recognize the shape and pose of a hand
from the 3-dimensional (3D)-depth data, provided real-time
3D-coordinates of the wrist, the finger joints, and the finger tips
at a sampling rate of 30 Hz. D-flow software16 (Motekforce
TABLE 1 Patient characteristics
Characteristic Total Test-retest
Total no. 57 12
Sex: Men/women, no. 36/21 6/6
Age: Mean  SD, y 65.2  8.8 69.4  6.5
Disease duration, y 12.6  6.8 14.3  6.8
Hoehn and Yahr stage:
Median (range)a
3 (1-5) 3 (2-4)
MDS-UPDRS-IIIb 36.6  16.3 39.1  14.6
SD, standard deviation; MDS-UPDRS-III, International Parkinson and
Movement Disorders Society-sponsored revision of the Unified
Parkinson’s Disease Rating Scale, part III (motor evaluation).
aHoehn and Yahr staging ranges from 0 to 5, with higher stages
indicating worse disease.
bMDS-UPDRS-III scores range from 0 to 132, with higher scores indi-
cating worse disease.
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Link, Amsterdam, the Netherlands), expanded with a data fusion
component (NCF; Noldus, Wageningen, the Netherlands), was
used for controlling the experiment and data storage.
Throughout the experiment, participants sat upright in a
chair with their feet supported. Before each task, instructions
were presented on a 60-inch LED TV (LC-60LE652E; Sharp
Electronics Europe Ltd., Usbridge, UK) placed approximately
1.5 m in front of the participant’s head. The task was demon-
strated both on screen and live by the experimenter. Participants
first performed a 10-second practice trial at comfortable speed
with the widest possible amplitude, followed by a short break,
then the actual 20-second measurement. For the actual mea-
surement, participants were instructed to perform the move-
ment as fast as possible and with the widest possible amplitude.
Patients performed the tasks with their most affected hand
(i.e., the hand with the highest total score on the Items 3.4
through 3.6 of the motor evaluation subscale [part III] of the
MDS-UPDRS). Controls were randomly assigned to perform
the tasks with either their dominant (N = 29) or nondominant
(N = 28) hand (as assessed using a Dutch version of the Edin-
burgh Handedness Questionnaire17). All participants were
instructed to keep both hands in view of the sensor, holding
their inactive hand still under the sensor with palm down and
fingers extended and slightly spread, to improve detection of
the contralateral, active hand. To ensure optimal hand detec-
tion, RFT was performed at an angle of approximately 45
degrees relative to the camera, and AHM was performed with
the palm down. During the actual measurement, the estimated
hand model was checked in real time by the experimenter on a
second screen, which was not visible to the participant. The
task was repeated in case there were problems with hand detec-
tion. The order of the 3 tasks was randomized across partici-
pants. For participants in the “test-retest” study, the same order
was kept between measurements.
Data Analysis
Occasionally, the software failed to fit a hand model. Data seg-
ments were considered representative of the participant’s perfor-
mance and selected for analysis if they met the following
requirements: a minimum duration of 5 seconds, a minimum of
80% of valid data points, and free from episodes of 4 or more
consecutive missing data points. In approximately 76% of all tri-
als, this yielded 1 valid data segment (average duration  stan-
dard deviation, 16.3  4.2 seconds). In approximately 8% of
the trials, multiple shorter segments (each >5 seconds) were
identified. For these trials, outcome parameters were calculated
per segment, and their weighted average was calculated (based
on segment duration). Sixteen percent of all trials were
excluded from further analyses because no segment met the
requirements (the large majority concerned AFM) (Table 2).
Data analysis was performed using custom-made scripts in
MATLAB (The MathWorks Inc., Natick MA; version R2016a;
interested readers are invited to contact the corresponding
author for the post-processing scripts). Data from selected seg-
ments were resampled to a uniformly distributed discrete time
FIG. 1. Impression of (A) the optical hand tracking setup and (B–D) the 3 tasks: (B) repetitive finger tapping, an analysis based on the
distance between distal joints of the thumb and index finger (in cm); (C) alternating hand movements, an analysis based on the “sur-
face” of the hand (in cm2); and (D) alternating forearm movements, an analysis based on the orientation of the line between the base of
the index finger and the base of the pinky in the frontal plane (in degrees).
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series (30 Hz) using linear interpolation before a low-pass filter
was applied (fourth-order bidirectional Butterworth, 10 Hz).
For RFT, the distance (cm) between the distal joints of the
thumb and index finger was calculated (Fig. 1B). For AHM,
the surface of the hand (cm2) was calculated as the total surface
of 6 triangles, which were created by connecting 2 adjacent
points (i.e., from the distal joints of the fingers and the wrist)
with the approximate center of the hand (i.e., the mean of all
joint positions) (Fig. 1C). For AFM, the orientation of the line
between the base of the index finger and the base of the pinky
was calculated in the frontal plane (in degrees), with 0 degrees
indicating palm up, and 180 degrees indicating palm down
(Fig. 1D).
Separate parameters quantified (progressive reductions in)
speed, frequency, and amplitude and interruptions of rhythm. A
peak-detection algorithm was used to detect individual move-
ment cycles for the quantification of movement frequency (in-
verse of cycle duration) and amplitude (difference between the
cycle’s maximum excursion and the previous minimum).
Within each trial, the average movement frequency (fmean) and
amplitude (Amean) were calculated. Movement speed was quanti-
fied by means of the mean absolute velocity vmean. Changes in
frequency (Df), amplitude (DA), and velocity (Dv) were
obtained by linear regression over the time course of the trial.
Interruptions of rhythm were quantified by means of hesitations
(i.e., the surplus of times within a cycle that velocity changed
sign, calculated as the number of velocity zero crossings minus
the 2 reversals per cycle) and halts (i.e., the periods longer than
the average duration of 2 cycles, based on the mean frequency
of that trial, in which all data points fell within a range of
1.5 cm for RFT, 10 cm2 for AHM), or 30 degrees for AFM.
Halt duration was expressed as a percentage of the total dura-
tion of included data segments.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 23.0
(IBM Corporation, Armonk, NY). Analyses were conducted
separately for the different tasks. Normality curves were
inspected, and Kolmogorov-Smirnov tests were used to assess
whether the data were normally distributed.18 Values of nor-
mally distributed variables are presented as means  standard
deviations, and all other values are presented as medians with
interquartile ranges.
Cross-sectional analysis
Independent-samples t tests (for normally distributed variables)
or Mann-Whitney U tests (for other variables) were used to
compare outcomes between patients with PD and controls. For
t tests, degrees of freedom were adjusted if the assumption of
homogeneity of variance was violated.18 Values for Df, DA, and
Dv were submitted to 1-sample t tests (for normally distributed
variables) or Wilcoxon signed-rank tests (for other variables) to
determine whether they differed significantly from zero. Signifi-
cance was set at P < 0.05. Within the PD group, Kendall’s s
was used to examine correlations between the quantitative kine-
matic parameters and the score on the corresponding item of
the MDS-UPDRS.
Test-retest and intra-trial reliability
Test-retest reliability for kinematic parameters was assessed by
means of the intraclass correlation coefficient for absolute agree-
ment (ICCA,1)
19 based on all participants in the test-retest study
(i.e., controls and patients with PD combined). With data from
24 participants, a good ICC of 0.65 would at least be detected
TABLE 2 Overview of excluded trials and their distribution over experimental tasks
Experimental task No. in study part No. in analysis (%) No. not in analysis
Task not performed Technical issues No segment
Repetitive finger tapping
Cross-sectional
PD 57 52 (91) 2 1 2
Control 57 53 (93) 0 1 3
Test-retesta
PD 12 10 (83) 0/0 0/2 0/0
Control 12 11 (92) 0/0 0/0 0/1
Alternating hand movements
Cross-sectional
PD 57 52 (91) 2 2 1
Control 57 53 (93) 0 2 2
Test-retesta
PD 12 8 (67) 0/0 0/2 0/2
Control 12 12 (100) 0/0 0/0 0/0
Alternating forearm movements
Cross-sectional
PD 57 40 (70) 2 4 11
Control 57 24 (42) 0 0 33
Test-retesta
PD 12 6 (50) 0/0 3/2 1/2
Control 12 3 (25) 0/0 0/2 7/7
PD, Parkinson’s disease.
aReported values for the number not in analysis are for the first and second measurements, respectively (separated by /).
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as being moderate (>0.4)20 (expected ICC = 0.65; 95% confi-
dence interval width = 0.46). In addition, we assessed intra-trial
reliability in all controls who were included in the cross-sec-
tional analysis to evaluate reliability in a situation where varia-
tion in performance was expected to be minimal. Assuming
that, in controls, task performance was constant over the time
course of a trial, we calculated the ICCA,1 of outcome parame-
ters derived from the first and last 5 seconds of each trial.
ICCA,1 values above 0.40 were considered fair, values above
0.60 were considered good, and values above 0.75 were consid-
ered excellent.21 ICCA,1 values were complemented by mean
differences and precision values obtained with a Bland-Altman
analysis (i.e., the bias and limits of agreement).22
Results
OHT was successful in evaluating the RFT and AHM tasks in
94% of all participants who performed these tasks. Failure was
caused by technical problems or the lack of a data segment that
met the requirements; for the AFM task, no data segment could
be selected in 44 participants because of problems with hand
recognition during fast alternation between pronation and
supination (Table 2). This was particularly evident in the con-
trol group, in which only 42% of participants had more than
10 seconds of data available for analysis. Therefore, AFM was
excluded from further analysis. Two patients with PD were
unable to perform the tasks due to fatigue (caused by the larger
study protocol of which this experiment was part). An overview
of excluded trials and their distribution over experimental tasks
is presented in Table 2.
Cross-sectional Analysis
The patients with PD performed the RFT task with signifi-
cantly reduced velocity, frequency, and amplitude and with
more hesitations and halts than controls (Table 3). In addition,
patients displayed a more pronounced decrement of frequency
than controls (i.e., Df was more negative but was not signifi-
cantly smaller than zero). For the patients with PD, higher
scores on the MDS-UPDRS item for RFT were associated
with reduced velocity and frequency, more hesitations, and
longer halt duration (Table 3).
TABLE 3 Results of cross-sectional analysis
Experimental task Control, N = 53 PD, N = 52 P value Correlation with
MDS-UPDRS item
Repetitive finger tapping (RFT)
Velocity (v)
vmean, cm.s
1 24.9  6.2 16.1  8.0 <0.001a 0.37**
Dv, cm.s2 0.22 (0.43, 0.11)c 0.29 (0.51, 0.08)c 0.14b 0.03
Frequency (f)
fmean, cycles.s
1 2.5  0.9 2.2  0.8 0.027a 0.24 *
Df, cycles.s2 0.003 (0.01, 0.02) 0.01 (0.03, 0.01) 0.032b 0.05
Amplitude (A)
Amean, cm 5.6  1.6 4.1  2.0 < 0.001a 0.16
DA, cm.s1 0.05 (0.12, 0.01)c 0.06 (0.13, 0.01)c 0.791b 0.04
Interruptions of rhythm
Hesitations, no.cycle1 0.4 (0.2–0.8) 0.8 (0.3–1.6) 0.007b 0.31*
Halts, % of time 0 (0–0) 0 (0–21.6) <0.001b 0.27*
Clinical assessment
Total MDS-UPDRS-III — 36.2  16.1 — —
RFT item 3.4 — 2 (1–3) — —
Alternating hand movements (AHM)
Velocity (v)
vmean, cm.s
1 110.8  37.3 84.6  31.3 <0.001a 0.41**
Dv, cm.s2 0.2  2.0 0.7  2.5c 0.24a 0.11
Frequency (f)
fmean, cycles.s
1 1.8  0.6 1.5  0.4 0.005a 0.39**
Df, cycles.s2 0.0004  0.03 0.005  0.03 0.42a 0.05
Amplitude (A)
Amean, cm 34.2  12.2 29.5  9.4 0.03a 0.17
DA, cm.s1 0.21  0.62c 0.35  0.58c 0.23a 0.11
Interruptions of rhythm
Hesitations, no.cycle1 3.4 (2.9–4.4) 3.7 (3.2–4.5) 0.33b 0.35*
Halts, % of time 0 (0–0) 0 (0–0) 0.04b 0.10
Clinical assessment
Total MDS-UPDRS-III – 36.5  16.6 – –
AHM item 3.5 – 1 (1–2) – –
D, change; PD, Parkinson’s disease; MDS-UPDRS-III, International Parkinson and Movement Disorders Society-sponsored revision of the Uni-
fied Parkinson’s Disease Rating Scale.
aThese P values were determined using an independent-sample t test and parameter values are presented as the mean  standard deviation.
bThese P values were determined using the Mann-Whitney U test and parameter values are presented as the median (interquartile range).
cThese values are significantly different from 0 (using the Wilcoxon signed-rank test; P < 0.05). Asterisks indicate significant correlations
between kinematic parameters and the score on the corresponding MDS-UPDRS item: *P < 0.05; **P < 0.01.
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Patients with PD performed the AHM task with significantly
reduced velocity, frequency, and amplitude and with more halts
than controls (Table 3). For the patients with PD, higher scores
on the MDS-UPDRS item for AHM were associated with




The self-reported function of the arm and hand was rated 5
(i.e., “unchanged” compared with the first measurement) by all
controls and by 11 of 12 the patients with PD who participated
in the test-retest study; 1 patient with PD reported a 1-point
(out of a possible 5-point) reduction.
For the RFT task, test-retest reliability was fair for amplitude,
good for velocity, and excellent for halts, with relatively small
bias and narrow limits of agreement for these parameters
(Table 4). Test-retest reliability was poor for frequency and for
changes of velocity (Dv), frequency (Df), and amplitude (DA),
with ICCA,1 values <0.20 in combination with large bias and/or
wide limits of agreement relative to the average parameter values.
For the AHM task, fair-to-good test-retest reliability was
observed for frequency, with relatively small bias and narrow lim-
its of agreement (Table 4), whereas test-retest reliability of the
other kinematic variables was poor (all ICCA,1 values ≤ 0.25).
The intra-trial ICCA,1 (based on outcome parameters derived
from the first and last 5 seconds of each trial in controls) was
excellent for frequency, good for velocity, and fair for ampli-
tude and hesitations on the RFT task (Table 4). Excellent intra-
trial reliability was observed for velocity, frequency, and ampli-
tude on the AHM task (Table 4), whereas reliability of hesita-
tions was fair on this task.
Discussion
OHT used for objective assessment of the movement compo-
nents of bradykinesia of the upper extremity in PD showed
promise with regard to finger tapping (RFT) and hand opening
and closing (AHM): key kinematic parameters differed between
patients with PD and healthy controls and were correlated with
corresponding scores on the MDS-UPDRS, indicating that
characteristic features of PD were successfully captured in objec-
tive parameters.
Test-retest reliability was fair or good for velocity, amplitude,
and halts on the RFT item and for frequency on the AHM
item. The test-retest reliability of the other kinematic variables,
such as amplitude and halts on the AHM item, however, was
poor, with ICCA,1 values below 0.25. For comparison, test-ret-
est reliability has been reported as poor to fair23–25 or good7,26
for individual bradykinesia items on the MDS-UPDRS (ICC
values ranging from 0.21 to 0.80) and as fair or good for items
TABLE 4 Results for test-retest and intra-trial reliability
Experimental task Test-retest reliability and agreementa Intra-trial reliability and agreement: First 5
s vs. last 5 s of trial in controlsb
ICCA,1 Bias (limits of agreement) ICCA,1 Bias (limits of agreement)
Repetitive finger tapping (RFT)
Velocity (v)
vmean, cm.s
1 0.72 1.1 (2.1, 4.3) 0.71 0.5 (0.8, 1.9)
Dv, cm.s2 0.17 0.01 (0.3, 0.3) — —
Frequency (f)
fmean, cycles.s
1 0.12 0.4 (0.1, 0.8) 0.91 0.08 (0.03, 0.19)
Df, cycles.s2 0.19 0.02 (0.05, 0.01) — —
Amplitude (A)
Amean, cm 0.40 0.08 (1.0, 0.9) 0.48 0.02 (0.7, 0.7)
DA, cm.s1 0.01 0.05 (0.03, 0.12) — —
Interruptions of rhythm
Hesitations, no.cycle1 0.18 0.4 (1.0, 0.1) 0.42 0.04 (0.3, 0.2)
Halts, % of time 0.90 3.1 (8.6, 2.3) — —
Alternating hand movements (AHM)
Velocity (v)
vmean, cm.s
1 0.22 7.8 (30.0, 14.3) 0.76 4.8 (4.2, 13.8)
Dv, cm.s2 0.17 0.8 (2.3, 0.7) — —
Frequency (f)
fmean, cycles.s
1 0.59 0.1 (0.1, 0.4) 0.81 0.004 (0.1, 0.1)
Df, cycles.s2 0.01 0.01 (0.02, 0.04) — —
Amplitude (A)
Amean, cm 0.25 4.2 (9.8, 1.4) 0.82 3.8 (6.5, 1.0)
DA, cm.s1 0.07 0.02 (0.6, 0.6) — —
Interruptions of rhythm
Hesitations, no.cycle1 0.11 0.2 (1.0, 0.5) 0.41 0.7 (1.6, 0.2)
Halts, % of time 0.21 1.1 (3.3, 1.1) — 1.6 (3.9, 0.6)
D, change; ICCA,1, intraclass correlation coefficient for absolute agreement.
aBased on N = 21 for RFT and N = 20 for AHM.
bBased on N = 53 for RFT and AHM. Reported variables were assumed to be constant over the time course of a trial in controls. Variables
Dv, Df, and DA were excluded from this analysis, because the 5-second segments were considered too short to quantify changes in velocity,
frequency, and amplitude.
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on the Modified Bradykinesia Rating Scale (ICC values ranging
from 0.45 to 0.83).3,7 To date, reports on test-retest reliability
of technology-based sensors for bradykinesia assessment are
scarce. Heldman et al.7 reported a within-session ICC for con-
sistency of 0.63 for rhythm and 0.94 for speed and amplitude of
RFT using IMU technology. These values are slightly higher
than the “stricter” ICC values for absolute agreement obtained
in the present study (i.e., 0.90 for halts, 0.72 for velocity, and
0.40 for amplitude), where the time interval between 2 mea-
surements was considerably longer.
Three possible reasons can be put forward for the disappoint-
ing test-retest reliability of several kinematic parameters in the
current study: (1) instrument-based error, (2) change in health
status between measurements, and (3) change in movement
strategy. With regard to the potential role of instrument-based
error, it is unfortunate that there are no reports on the validity
and accuracy of the 3D hand model used for OHT. Also, in
the current study, the instrument-based error could not be eval-
uated by means of a direct comparison of OHT with a gold-
standard reference system, because performance of the OHT
algorithm would be compromised by the attachment of markers
or sensors to the hand. However, the high intra-trial reliability
(i.e., ICCA,1 values for outcome parameters derived from the
first and last 5 seconds of each trial in controls) for both RFT
and AHM indicates that the setup measured similar kinematics
when performance was assumed to be constant. This finding
strongly suggests that the low test-retest reliability for ampli-
tude, velocity, frequency, and hesitations observed in this study
is not likely caused by instrument-based error. It is also not
plausible that the low test-retest reliability is attributable to
changes in the participants’ health status, given the 1-week
interval between measurements and the fact that most partici-
pants reported no change in function of the arm and hand.
Moreover, the same order of tasks was retained so that the
effects of fatigue would be similar, and measurements were per-
formed at the same time of the day (and thus at the same time
after medication intake) to minimize the effects of motor fluc-
tuations in patients. Despite these measures, it cannot be fully
ruled out that non-constant effects of PD medication in patients
might have led to slight underestimation of test-retest reliability
and correlations with the MDS-UPDRS scores. However, it
seems more likely that participants applied different strategies
during the 2 measurement sessions, because the task instructions
were open to different interpretations (i.e., according to the
MDS-guidelines, the movement should be performed as wide
and as fast as possible).This hypothesis of strategy change is sup-
ported by a strong negative correlation between the changes in
amplitude and frequency from the first to the second measurement for
RFT (r = 0.69), but not for AHM (r = 0.07) (see
Fig. S1). The negative correlation for RFT indicates that partic-
ipants may have put more emphasis on a high movement fre-
quency (at the cost of smaller amplitude) during one
measurement and more emphasis on movement amplitude (at
the cost of lower movement frequency) during the other mea-
surement. This strategy change between measurements would
result in low test-retest reliability of these individual variables.
Because velocity reflects a combination of amplitude and fre-
quency, one might expect that velocity would be less suscepti-
ble to changes in strategy than amplitude and frequency
separately, which was indeed the case for RFT. For the AHM
task, a low ICCA,1 was also observed for velocity, possibly
because velocity was more strongly associated with amplitude
(r = 0.88) than with frequency (r = 0.45), whereas amplitude in
particular appeared to be subject to test-retest variation (as was
indicated by lower ICCA,1 values) (Table 4). In line with this
finding, velocity and halts appeared to be the most useful vari-
ables for quantification of RFT, whereas frequency appeared
most the useful for quantification of AHM (Fig. 2). These find-
ings suggest that quantification of these movement components
is recommendable for monitoring patients or evaluating treat-
ment effects.
Against this background, the absence of strong correlations
between kinematic parameters and clinical scores may not be
surprising, particularly because clinical scores may reflect differ-
ent combinations of multiple movement components. Notably,
for technological developments, a strong agreement between
quantitative measures and subjective clinical scores, the so-called
“clinimetric validation pitfall”, is not necessarily required. A
“perfect” objective measurement should have a complicated
quantitative match with an “imperfect” subjective measurement
(Espay et al.,5 p. 1279). Technology-based outcome measures
should show improved resolution, reliability, and/or responsive-
ness relative to the widely used clinical rating scales. Our find-
ings indicate that individual parameters are susceptible to
variations in movement strategy, which may suggest that task
performance is better captured by a combination of kinematic
FIG. 2. Schematic indication of the “usability” of each out-
come parameter based on its ability to distinguish between
patients with Parkinson’s disease and controls (larger circles
indicate a more prominent difference between patients with
PD and controls) and test-retest reliability (darker color indi-
cates a higher intraclass correlation coefficient for absolute
agreement). The largest, darkest circles indicate the best
outcome parameters.
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outcome parameters. We have explored several options in this
regard. The strong covariance between velocity, frequency, and
amplitude did not allow an analysis of the combination of vari-
ables by either logistic regression models, principal component
analysis, or linear discriminant analysis. Therefore, as an alterna-
tive, we explored the potential of “sum scores” based on cutoff
values for each outcome parameter (see the online Supporting
Materials and Tables S1–S4). This seemed promising for the
identification of severely affected patients with PD, but it could
not distinguish between mildly affected patients with PD and
healthy participants.
OHT for the objective quantification of bradykinesia has a
great advantage in terms of patient-friendly assessment, because
it does not require preparation time or attachment of sensors,
which can affect movements of the fingers and/or hands. The
results seem to be unaffected by slight variations in orientation
of the hand relative to the sensor, and the sampling rate appears
to be sufficient for evaluating RFT and AHM. Current
limitations in post-processing (e.g., the manual correction of
peak-detection errors that was required in some cases) need to
be further improved and automated in the future. The system
appeared insufficiently able to evaluate the AFM item, because
rapid alterations between pronation and supination hampered
hand recognition. Consequently, this task may only discriminate
the more affected, slower moving patients with PD (see
Table 2). Currently, approaches that are not based on algo-
rithms for hand recognition in real time (e.g., using an
IMU,3,4,27,28 gyroscope,29,30 or accelerometer31) appear to be
more suitable for the quantification of pronation and supina-
tion.
In conclusion, OHT yielded promising results for the assess-
ment of bradykinesia of the upper extremity in PD. Separate
quantification of velocity and halts for RFT and frequency for
AHM is recommended for monitoring patients or evaluating
treatment effects. Future work should address approaches to
combining kinematic parameters to better understand and
reduce the measurement’s susceptibility to changes in strategy
and to enhance responsiveness to changes in the patient’s actual
health status (e.g., induced by dopaminergic medication).
Authors’ Roles
1. Research Project: A. Conception, B. Organization, C. Exe-
cution; 2. Statistical Analysis: A. Design, B. Execution, C.
Review and Critique; 3. Manuscript Preparation: A. Writing
the First Draft, B. Review and Critique.
P.J.M.B.: 1A, 1B, 1C, 2A, 2B, 3A
J.M.: 1A, 1B, 2C, 3B
J.H.d.G.: 1A, 2C, 3B
C.G.M.M.: 1A, 1C, 2C, 3B
J.J.v.H.: 1A, 3B
Acknowledgments
We thank Leo Casteel, MSc, Rosanne van Tol, MSc, and Elma
Ouwehand, MSc, for their help in collecting the data.
Disclosures
Ethical Compliance Statement: We confirm that we have
read the Journal’s position on issues involved in ethical publica-
tion and affirm that this work is consistent with those guide-
lines.
Funding Sources and Conflicts of Interest: This work is
part of the research program IMDI Neurocontrol (NeurAS pro-
ject 10-10400-98-008) financed by the Netherlands Organisa-
tion for Health Research and Development and the research
program Technology in Motion (TIM) (628.004.001), which is
financed by the Netherlands Organisation for Scientific
Research. The authors declare that there are no conflicts of
interest relevant to this work.
Financial Disclosures for the past 12 months: P.J.M. Bank
is employed by the Leiden University Medical Center based
on funding by the Netherlands Organisation for Scientific
Research (NWO) (628.004.001), and received a grant from
the “Stichting Wetenschapsfonds Dystonie.” J. Marinus is
employed by the Leiden University Medical Center, received a
grant from the “Stichting ParkinsonFonds” and received hono-
raria from the International Parkinson and Movement Disor-
ders Society. J.H. de Groot is employed by the Leiden
University Medical Center, received a grant from the Technol-
ogy Foundation STW, and is member of the advisory board of
the Netherlands Society of Rehabilitation Medicine-Research
Commission. C.G.M. Meskers is employed by the VU
University Medical Center, received grants from the Technol-
ogy Foundation STW and the Netherlands Organisation for
Health Research and Development, received a personal grant
from the Dutch Brain Foundation, and is member of the sci-
entific advisory board of Motekforce Link. J.J. van Hilten is
employed by the Leiden University Medical Center; he
received grants from the Alkmade-Keuls Foundation, the
“Stichting ParkinsonFonds,” the Parkinson Vereniging, the
Dystonie Vereniging and the Netherlands Organisation for
Health Research and Development.
Orcid
Paulina J.M. Bank http://orcid.org/0000-0002-3127-398X
References
1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria
for Parkinson’s disease. Mov Disord 2015;30:1591–1601.
2. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Soci-
ety-sponsored revision of the Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS): scale presentation and clinimetric testing results. Mov
Disord 2008;23:2129–2170.
3. Heldman DA, Giuffrida JP, Chen R, et al. The Modified Bradykinesia
Rating Scale for Parkinson’s disease: reliability and comparison with
kinematic measures. Mov Disord 2011;26:1859–1863.
4. Espay AJ, Giuffrida JP, Chen R, et al. Differential response of speed,
amplitude, and rhythm to dopaminergic medications in Parkinson’s dis-
ease. Mov Disord 2011;26:2504–2508.
5. Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson’s dis-
ease: challenges and opportunities. Mov Disord 2016;31:1272–1282.
882 MOVEMENT DISORDERS CLINICAL PRACTICE
doi:10.1002/mdc3.12536
OPTICAL HAND TRACKING TO ASSESS BRADYKINESIARESEARCH ARTICLE
6. Kishore A, Espay AJ, Marras C, et al. Unilateral versus bilateral tasks in
early asymmetric Parkinson’s disease: differential effects on bradykinesia.
Mov Disord 2007;22:328–333.
7. Heldman DA, Espay AJ, LeWitt PA, Giuffrida JP. Clinician versus
machine: reliability and responsiveness of motor endpoints in Parkin-
son’s disease. Parkinsonism Relat Disord 2014;20:590–595.
8. Sanchez-Ferro A, Elshehabi M, Godinho C, et al. New methods for the
assessment of Parkinson’s disease (2005 to 2015): a systematic review.
Mov Disord 2016;31:1283–1292.
9. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantita-
tive wearable sensors for objective assessment of Parkinson’s disease.
Mov Disord 2013;28:1628–1637.
10. Del Din S, Godfrey A, Mazza C, Lord S, Rochester L. Free-living
monitoring of Parkinson’s disease: Lessons from the field. Mov Disord
2016;31:1293–1313.
11. Goetz CG, Stebbins GT, Wolff D, et al. Testing objective measures of
motor impairment in early Parkinson’s disease: feasibility study of an at-
home testing device. Mov Disord 2009;24:551–556.
12. Homann CN, Suppan K, Wenzel K, et al. The Bradykinesia Akinesia
Incoordination Test (BRAIN TEST), an objective and user-friendly means
to evaluate patients with Parkinsonism. Mov Disord 2000;15:641–647.
13. Taylor Tavares AL, Jefferis GS, Koop M, et al. Quantitative measure-
ments of alternating finger tapping in Parkinson’s disease correlate with
UPDRS motor disability and reveal the improvement in fine motor
control from medication and deep brain stimulation. Mov Disord
2005;20:1286–1298.
14. Memedi M, Khan T, Grenholm P, Nyholm D, Westin J. Automatic
and objective assessment of alternating tapping performance in Parkin-
son’s disease. Sensors (Basel) 2013;13:16965–16984.
15. Gibb W, Lees A. The relevance of the Lewy body to the pathogenesis
of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry
1988;51:745–752.
16. Geijtenbeek T, Steenbrink F, Otten B, Even-Zohar O. D-flow: immer-
sive virtual reality and real-time feedback for rehabilitation. In: Proceedings
of the 10th International Conference on Virtual Reality Continuum and
Its Applications in Industry; December 22–12, 2011; Hong Kong, China.
New York, NY: Association for Computing Machinery; 2011:201–208.
17. Oldfield RC. The assessment and analysis of handedness: the Edinburgh
inventory. Neuropsychologia 1971;9:97–113.
18. Field A. Discovering Statistics Using SPSS. London, UK: Sage Publica-
tions; 2009.
19. de Vet HC, Terwee CB, Knol DL, Bouter LM. When to use agree-
ment versus reliability measures. J Clin Epidemiol 2006;59:1033–1039.
20. Shoukri MM, Asyali MH, Donner A. Sample size requirements for the
design of reliability study: review and new results. Stat Methods Med Res
2004;13:251–271.
21. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating
normed and standardized assessment instruments in psychology. Psychol
Assess 1994;6:284–290.
22. Bland JM, Altman DG. Measuring agreement in method comparison
studies. Stat Methods Med Res 1999;8:135–160.
23. Camicioli R, Grossmann SJ, Spencer PS, Hudnell K, Anger WK. Dis-
criminating mild parkinsonism: methods for epidemiological research.
Mov Disord 2001;16:33–40.
24. Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assess-
ment of motor impairments and disabilities in Parkinson’s disease: the
SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004;75:388–395.
25. Bennett DA, Shannon K, Beckett LA, Goetz C, Wilson R. Metric
properties of nurses’ ratings of parkinsonian signs with a modified
Unified Parkinson’s Disease Rating Scale. Neurology 1997;49:1580–
1587.
26. Siderowf A, McDermott M, Kieburtz K, et al. Test-retest reliability of
the unified Parkinson’s disease rating scale in patients with early Parkin-
son’s disease: results from a multicenter clinical trial. Mov Disord
2002;17:758–763.
27. Mera TO, Heldman DA, Espay AJ, Payne M, Giuffrida JP. Feasibility
of home-based automated Parkinson’s disease motor assessment. J Neu-
rosci Methods 2012;203:152–156.
28. Piro NE, Piro LK, Kassubek J, Blechschmidt-Trapp RAAnalysis and
visualization of 3D motion data for UPDRS rating of patients with
Parkinson’s disease. Sensors (Basel) 2016;16: pii:E930.
29. Tabbal SD, Ushe M, Mink JW, et al. Unilateral subthalamic nucleus
stimulation has a measurable ipsilateral effect on rigidity and bradykinesia
in Parkinson disease. Exp Neurol 2008;211:234–242.
30. Jun JH, Kim JW, Kwon Y, et al. Quantification of limb bradykinesia in
patients with Parkinson’s disease using a gyrosensor—improvement and
validation. Int J Precis Eng Manuf 2011;12:557–563.
31. Jia X, Duroseau N, Chan V, et al. Objective quantification of upper
extremity motor functions in Unified Parkinson’s Disease Rating Scale
Test. Conf Proc IEEE Eng Med Bio Soc 2014;2014:5345–5348.
Supporting Information
Additional Supporting Information may be found online in the
supporting information tab for this article:
Table S1. Cutoff values for repetitive finger tapping (RFT)
and alternating hand movements (AHM).
Table S2. Sum score results for repetitive finger tapping
(RFT) and alternating hand movements (AHM).
Table S3. Correlations of between-measurement changes in
kinematic parameters and in calculated scores for repetitive fin-
ger tapping (RFT) and alternating hand movements (AHM)
Table S4. Sensitivity and specificity of cutoff scores for dis-
criminating between patients with Parkinson’s disease and controls
Appendix S1. “Sum scores” to combine outcome parameters.
Figure S1. Correlation between the changes in amplitude and
frequency from the first (test) to the second (retest) measurement.
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